
Case Study
Same-Day Immunogenicity Turnaround: What an In-House Lab Changes
A look at how pairing an in-house bioanalytical laboratory with automated flow analysis changes the sponsor timeline for vaccine and immunology trials.
- Bioanalytical Lab
- Turnaround
- Vaccine Trials
Central laboratory turnaround for multi-color flow cytometry samples typically runs five to ten business days once shipping, batching, and manual analysis queues are accounted for. For a vaccine or immunotherapy trial tracking immune response kinetics across multiple timepoints, that lag can materially affect a sponsor's ability to make adaptive decisions.
Mount Clinical Research's bioanalytical laboratory processes flow cytometry, ELISpot/FluoroSpot, ELISA, and cytokine bead array samples on-site, eliminating the shipping and batching delay entirely. Paired with FlowAutoGate™ for automated gating, a same-day flow result is realistic for many panels — sample receipt to report in under 48 hours, rather than the industry-standard week or more.
The chain-of-custody benefits compound the speed benefit. Because samples never leave the building, there is no courier handoff, no freeze-thaw risk from transit delays, and a single, continuous audit trail from collection to report — all documented under our SOP library and 21 CFR Part 11-compliant electronic data management system.
For sponsors evaluating site partners for immunology-heavy protocols, we believe this combination of in-house processing and AI-assisted analysis represents a genuinely different turnaround-time offer, not an incremental improvement on the central-lab model.
Keep reading
More from the Resources Hub
- White Paper
Building an AI-Native Research Site From the First Patient Onward
Why sites built around AI from day one — rather than retrofitting legacy systems — hold a structural advantage sponsors are beginning to score for.
- Publication
FlowAutoGate™: Validation Methodology and Concordance Results
An overview of how FlowAutoGate™ was validated against expert manual gating, and what the results mean for sponsor-grade immunogenicity data.
- Blog
Why Chicago Is an Underused Advantage for Diverse Trial Enrollment
Chicago's demographic composition offers a rare combination of scale and diversity for sponsors navigating FDA diversity action plan requirements.
Partner with us
Let's design your next study for both speed and rigor.
Whether you need a full-service site, in-house bioanalytical support, or a FlowAutoGate™ pilot, our team can typically turn around a feasibility response within 5 business days.
